Previous Section | Index | Home Page |
4 Sep 2006 : Column 2122Wcontinued
Dr. Desmond Turner: To ask the Secretary of State for Health (1) what measures have been put in place to monitor the extent of the adoption of medical technologies in the NHS; [87029]
(2) what steps her Department is taking to ensure that budgetary pressures do not affect the use of the most effective medical technologies in the NHS. [87031]
Andy Burnham: There are no national measures in place specifically to monitor the adoption of non-drug medical technologies.
Guidance from the National Institute for Health and Clinical Excellence is an important tool in ensuring that national health service organisations prioritise clinically and cost effective interventions.
Jon Trickett: To ask the Secretary of State for Health how many NHS organisations have outsourced medical transcription services to (a) UK and (b) overseas organisations; what estimate she has made of the reduction in the number of medical secretary posts as a result of outsourcing; and what arrangements are in place for the evaluation of the impact of outsourcing these services in terms of (i) value for money and (ii) impact on patient care. [86148]
Ms Rosie Winterton: This information is not collected centrally.
Any decision to outsource medical transcription services and evaluate the impact of outsourcing these services is made by each national health service organisation in line with their business needs.
Mr. Stephen O'Brien: To ask the Secretary of State for Health whether the Medicine and Healthcare Products Regulatory Agency requirement of notification of shortages of medicine applies to parallel import licence holders in the same way as it is applied to the original manufacturer. [88879]
Andy Burnham: Articles 23a and 81 of Directive 2001/83/EC (as amended) relate directly to the supply of medicines, and require holders of marketing authorisationswithin the limits of their responsibilitiesto maintain appropriate and continued supplies of their products, and to notify the competent authority if a product is not going to be available either temporarily or permanently. The legislation requires two months notice in all but exceptional circumstances. Information supplied to the Medicines and Healthcare products Regulatory Agency (MHRA) is shared with medicines pharmacy and industry group in the Department.
Parallel import traders, for the purpose of the directive, are not holders of marketing authorisations and are not required to notify the MHRA. However, contractual terms and conditions with national health service trusts are applied to all suppliers equitably, whether manufacturers, traders or parallel importers.
Mr. Clegg: To ask the Secretary of State for Health what assessment she has made of the demand for expansion of the capacity of secure mental health units. [85419]
Ms Rosie Winterton: The requirement for secure mental health services is kept under regular review in order to inform the planning of the future development of psychiatric services at all levels of security.
A review of the forensic mental health system is being planned and scoping meetings have already taken place. This is underpinned by clear capacity planning for high and medium secure services that has already taken place and regional forensic commissioners in the national health service are validating the projections against their own regional strategies. New service models are emerging and regional commissioners have established a work programme that takes these models and the implications of the capacity requirements forward in a structured way.
Progress is being monitored through the high security psychiatric services national oversight group.
Mr. Clegg: To ask the Secretary of State for Health what the (a) average cost of a bed in a secure mental health ward and (b) total cost of secure mental health facilities was in the last year for which figures are available. [85420]
Ms Rosie Winterton: Information about the average costs of beds in secure mental health facilities for 2004-05, the latest year available, is contained in the publication NHS reference costs 2005 and in the following tables, which are also available on the Departments website at: www.dh.gov.uk/assetRoot/04/13/32/28/04133228.xls and www.dh.gov.uk/assetRoot/04/13/32/29/04133229.xls
Next Section | Index | Home Page |